Andrew Dickinson

Executive Vice President & Chief Financial Officer at Gilead Sciences, Inc.

Andrew Dickinson

Andrew Dickinson

Executive Vice President & Chief Financial Officer at Gilead Sciences, Inc.

Overview
Career Highlights

Myogen, Inc.
Gilead Sciences, Inc.
Immunomedics Inc.

RelSci Relationships

1360

Number of Boards

4

Birthday

1970

Age

51

Contact Data
Trying to get in touch with Andrew Dickinson? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Andrew Dickinson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Vice President, Corporate Affairs & General Counsel at Gilead Sciences, Inc.

Relationship likelihood: Strong

Non-Resident Fellow at The Salk Institute for Biological Studies

Relationship likelihood: Strong

Associate Professor at Stanford University

Relationship likelihood: Strong

Managing Partner & Portfolio Manager at Avoro Capital Advisor LLC

Relationship likelihood: Strong

Executive Director at Immunomedics Inc.

Relationship likelihood: Strong

Co-Founder at Forty Seven, Inc.

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Gilead Sciences, Inc.

Relationship likelihood: Strong

Chief Executive Officer, Kite at Gilead Sciences, Inc.

Relationship likelihood: Strong

Former Chief Commercial Officer & Executive Vice President at Ipsen SA

Relationship likelihood: Strong

Senior Vice President, Corporate Controller & Chief Accounting Officer at Gilead Sciences, Inc.

Relationship likelihood: Strong

Paths to Andrew Dickinson
Potential Connections via
Relationship Science
You
Andrew Dickinson
Executive Vice President & Chief Financial Officer at Gilead Sciences, Inc.
Education
Class of 1996

Loyola University Chicago, a private university founded in 1870 as St. Ignatius College, is one of the nation’s largest Jesuit, Catholic Universities and the only one located in Chicago. Loyola University Chicago comprises four campuses: Lake Shore (LSC), Water Tower (WTC), Health Sciences (HSC), and the John Felice Rome Center in Italy, and is home to ten schools and colleges: Quinlan School of Business, Marcella Niehoff School of Nursing, Stritch School of Medicine, College of Arts and Sciences, School of Communication, School of Continuing and Professional Studies, School of Education, School of Law, School of Social Work, and Graduate School. Loyola also features course locations in Beijing, China; Saigon-Ho Chi Minh City, Vietnam; Vernon Hills, Illinois (Cuneo Mansion and Gardens); and a Retreat and Ecology Campus in Woodstock, Illinois.

Class of 1993

The University of Colorado advances the economy, health and culture of Colorado and beyond, educating more than 435,000 students who have become catalysts in business, arts, health, and community growth. CU's four campuses feature top-tier faculty and hands-on learning opportunities in an environment where students thrive.

Career History
President, Treasurer & Director
2020 - Current

Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

President, Treasurer & Director
2020 - Current

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Executive Vice President & Chief Financial Officer
2016 - Current

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Political Donations
$250
2010
Transactions
Details Hidden

STERIS Corporation purchases Synergy Health Ltd.

Details Hidden

GlaxoSmithKline Plc purchases Novartis AG /Human Vaccines Operations from Novartis AG

Details Hidden

Chiesi Farmaceutici SpA purchases Chiesi USA, Inc.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Andrew Dickinson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Andrew Dickinson's profile does not indicate a business or promotional relationship of any kind between RelSci and Andrew Dickinson.